The majority of experts and opinion leaders believe that artificial intelligence (AI) is going to revolutionise many industries, including healthcare \[[@CR1]\]. In the short term, the power and potential of AI appear most suitable for complementing human expertise. In other words, machines will help humans do a better job. Consequently, it is anticipated that AI will help with repetitive tasks, in-depth quantification and classification of findings, improved patient and disease phenotyping and, ultimately, with better outcomes for patients, physicians, hospital administrators, insurance companies and governments \[[@CR2]\].

Despite these promises, the impact of AI in current clinical practice is still limited. However, this could change in the coming years, as illustrated by the significant increase in papers in AI, machine learning and deep learning in cardiology (Fig. [1](#Fig1){ref-type="fig"}). Moreover, multiple applications have gained Federal Drug Administration approval in recent years with significant financial support; these are directly related to daily cardiology practice, including automated interpretation of electrocardiograms, automated segmentation and diagnosis (Tab. [1](#Tab1){ref-type="table"}). Common practice in invasive cardiology will be seriously influenced by AI, for example by predicting the outcome of interventions such as transcatheter aortic valve implantation or AI-based non-invasive estimation of the haemodynamic significance (CT fractional flow reserve) of coronary artery stenosis on CT angiography that is being developed by different companies \[[@CR3]--[@CR5]\].Fig. 1Proportion of citations on PubMed (1998--2018) for each search per year for key terms (source: http://esoerr.github.io/pubmed-by-year)Table 1Federal Drug Administration approvals of artificial intelligence (*AI*) applications relevant for cardiology practiceYearCompanyAI application2014AlivecorDetection of atrial fibrillation2016LumifyUltrasound image diagnosis2017ArterysCardiac MRI ventricle segmentation2017BiofluxDetecting arrhythmias2017CardiologsECG analysis2018Lepu MedicalECG analysis2018Zebra Medical VisionAutomated coronary artery calcification2018Physiq Heart Rhythm ModuleDetection of atrial fibrillation2018AppleDetection of atrial fibrillation2018Bay LabsEchocardiogram analysis2019VerilyECG feature on Study Watch2019AlivecorSix-lead smartphone ECG2019Zebra Medical VisionRadiographic diagnosis2019AidocFlagging pulmonary embolism

This focus issue of the *Netherlands Heart Journal* aims to help general cardiologists explore the state of the art of AI in cardiology. It also aims to increase awareness that it is likely that AI is going to influence and even disrupt daily clinical practice and healthcare in general.

The first part of the issue will focus on past, present and future evidence and gives an overview in the form of two reviews on the impact of AI in cardiology and an area of more immediate impact, cardiovascular imaging \[[@CR6], [@CR7]\]. In the second part of this issue, several Dutch flagship AI projects are discussed and demonstrate the potential in various areas of AI as discussed above. These efforts not only concern clinical practical problems such as cardiovascular imaging and risk assessment, but also the need for multidisciplinary collaboration \[[@CR8]\] and dedicated data platforms to access and analyse the collected data \[[@CR9], [@CR10]\].

According to scientists from every decade since the 1960s, human-like AI should have been achieved within 10--20 years. However, mainly due to a lack of computational power, there have been two so-called 'winters' for AI around 1980 and 1993, both after a period of increased interest. But with the recent increase in computational power, smarter use of hardware and data, and new strategies such as deep learning, this appears to have changed for good. Artificial intelligence is likely to make its potential come true in the era of complex data, serving as a conduit to insight for doctors in their patient's data, improving efficiency and reducing errors.

Let's plan some randomised clinical trials!

J. Verjans declares that he has no competing interests. T. Leiner declares: Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: disclosed institutional grant received from Pie Medical B.V.; payments received from Bayer Healthcare and Philips Healthcare for lectures including service on speakers' bureaus. Other relationships: disclosed that he is coinventor of U.S. patent 10 176 575; this patent is held by Utrecht University Holdings, which manages the terms of any licensing agreement.
